مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

144
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

72
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Safety of Dapagliflozin in Type 1 Diabetes Patients

Pages

  45-58

Abstract

 Background and Purpose: The Dapagliflozin's safety profile in insulin-treated adult type-1 diabetes mellites (T1DM) patients remains poorly explored. Therefore, this systematic review and meta-analysis compared the risk of all-cause Side Effects, study discontinuation of participants due to Side Effects, urinary tract infection (UTI), diabetic ketoacidosis, and hypoglycemia between Dapagliflozin 10 mg and Dapagliflozin 5 mg, Dapagliflozin 10 mg and placebo, and Dapagliflozin 5 mg and placebo. Materials and Methods: Parallel-arm randomized controlled trials juxtaposing the above outcomes between the afore-mentioned interventions were eligible for inclusion in this study and were searched in PubMed, Embase, and Scopus. Utilizing the Cochrane tool, the risk of bias was assessed in the recruited trials. Finally, by random-effect meta-analysis, each outcome was compared among the above interventions, and the risk ratio was estimated. Results: Four trials of varying length (1-52 weeks) sourcing data from almost 1760 participants from about 32 nations were reviewed. Overall, the trials had a low or unclear risk of bias, and only one was at a high risk of bias. Compared to the placebo, the risk of Side Effects was higher in those treated with Dapagliflozin 5 mg (RR=1. 10; 95% CI=1. 02-1. 18; p=0. 014; I 2 =0%). UTI risk was less with the 10mg Dapagliflozin than its lower dose (RR=0. 50; 95% CI=0. 32-0. 79; pvalue=0. 003; I 2 =0%). All the remaining comparisons were statistically not significantly different between the juxtaposed intervention pairs. Conclusion: In contrast to placebo, Dapagliflozin 5mg increased the risk of overall adversities in insulin-treated type-1 diabetes, and Dapagliflozin 10 mg had a reduced risk of UTI than its 5mg preparation.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    Saha, Sumanta, & Saha, Sujata. (2020). A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Safety of Dapagliflozin in Type 1 Diabetes Patients. IRANIAN JOURNAL OF HEALTH SCIENCES, 8(2), 45-58. SID. https://sid.ir/paper/773497/en

    Vancouver: Copy

    Saha Sumanta, Saha Sujata. A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Safety of Dapagliflozin in Type 1 Diabetes Patients. IRANIAN JOURNAL OF HEALTH SCIENCES[Internet]. 2020;8(2):45-58. Available from: https://sid.ir/paper/773497/en

    IEEE: Copy

    Sumanta Saha, and Sujata Saha, “A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Safety of Dapagliflozin in Type 1 Diabetes Patients,” IRANIAN JOURNAL OF HEALTH SCIENCES, vol. 8, no. 2, pp. 45–58, 2020, [Online]. Available: https://sid.ir/paper/773497/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button